Gilead and Galapagos announce Filgotinib meets primary endpoint in the phase 3 Finch 3 study in Methotrexate-naïve rheumatoid arthritis patientsFriday, March 29, 2019
Gilead Sciences and Galapagos announced Week 24 results of FINCH 3, an ongoing, randomized, double-blind, active-controlled Phase 3 study of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis. FINCH 3 evaluated filgotinib in combination with methotrexate and as monotherapy in MTX-naïve patients. The study achieved its primary endpoint in the proportion of patients achieving an American College of Rheumatology 20 percent response (ACR20) at Week 24. The proportion of patients achieving the primary endpoint of ACR20 response at Week 24 was significantly higher for filgotinib 200 mg plus MTX and filgotinib 100 mg plus MTX compared with MTX alone.
ProQR receives fast track designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
20Med Therapeutics and Partners receive Eurostars Grant for the Development of New mRNA Therapeutics for Osteoarthritis
European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10